IceCure Medical Ltd. (ICCM) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and thank you for standing by. Currently, all of the participants are in listen-only mode. Thank you very much. Before we begin, I will now take a moment to read statements about forward-looking statements. This call and the question and answer session that follows it contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities law. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss the continued growth and sustainability of commercial adoption and utilization of process, the expansion of the company's U.S. and international commercial presence, the anticipated Enrollment of the first patients in, and continued expansion of the CHOICE study, the potential for clinical evidence and commercial utilization to support physician confidence, reimbursement initiatives, and broader market adoption. The company's commercialization efforts in Japan, the planned use for its financial resources, and the company's ability to execute its long-term growth strategy and create sustainable long-term shareholder value. The forward-looking statements contained or implied during this call are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the risk factors section of the company's annual report on Form 20-F. for the year ended December 31, 2025, filed with the SEC on March 17, 2026, which is available on the SEC's website, www.sec.gov. The company disclaim any intention or o...